Latest news
Chapel Hill drug developer's stock plunges 90% after trial setback - The Business JournalsThe Business Journals · Mon, 10 Aug 2026 19:48:00 GMTTenax's oral levosimendan misses primary endpoint in Phase 3 LEVEL PH-HFpEF trial - DealroomDealroom · Mon, 10 Aug 2026 16:55:56 GMTTenax Therapeutics (TENX) Shares Collapse 89% After Phase 3 Tria - GuruFocusGuruFocus · Mon, 10 Aug 2026 15:14:57 GMTTenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 15:03:31 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:03:24 GMTTenax sees 'clear path forward' for heart failure drug despite Phase III miss - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 14:47:17 GMTTenax trounced by phase 3 heart failure readout - pharmaphorumpharmaphorum · Mon, 10 Aug 2026 14:13:28 GMTTenax Therapeutics (TENX) Stock Drops 84% After Phase 3 LEVEL Trial Misses Primary Endpoint - CoinCentralCoinCentral · Mon, 10 Aug 2026 13:23:07 GMT